Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
24 janv. 2022 07h30 HE
|
Arbutus Biopharma Corporation
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for...